From: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
 | ITT Phase 2 | ITT Validation |
---|---|---|
N = 301 | N = 920 | |
Geographic area—no. (%) | ||
 Lombardia | 136 (45.2%) | 346 (37.6%) |
 Veneto | 65 (21.6%) | 41 (4.5%) |
 Emilia Romagna | 37 (12.3%) | 142 (15.4%) |
 Other Northern regions | – | 91 (9.9%) |
 Center | 39 (13.0%) | 186 (20.2%) |
 South and Islands | 24 (8.0%) | 114 (12.4%) |
Age—no. (%) | ||
  ≤ 60 | 122 (40.5%) | 375 (40.8%) |
 61–70 | 107 (35.5%) | 263 (28.6%) |
 71 +  | 72 (23.9%) | 282 (30.7%) |
Female sex—no. (%) | 59 (19.6%) | 200 (21.7%) |
Ethnic group—no. (%) | ||
 Caucasian | 271 (97.1%) | 853 (97.7%) |
 Asiatic | 3 (1.1%) | 2 (0.2%) |
 Other | 5 (1.8%) | 18 (2.1%) |
 Unknown | 22 | 47 |
Body mass index—no. (%) | ||
 Underweight/normal (< 25) | 75 (28.8%) | 192 (26.9%) |
 Overweight/obese (25 +) | 185 (71.2%) | 521 (73.1%) |
 Unknown | 41 | 207 |
Previous/actual smoker—No. (%) | 51 (22.2%) | 214 (29.2%) |
 Unknown | 71 | 188 |
Antiflu 2019 vaccination—No. (%) | 54 (25.0%) | 121 (20.3%) |
 Unknown | 85 | 325 |
Initial respiratory support—No. (%) | ||
 Oxygen supplementation | 146 (48.5%) | 468 (50.9%) |
 NIMV | 106 (35.2%) | 359 (39.0%) |
 IMV | 49 (16.3%) | 93 (10.1%) |
PaO2/FiO2 ratio—median (IQR) | 136 (93,198) | 154 (103,218) |
PaO2/FiO2 ratio—No. (%) |  |  |
  < 100 | 55 (32.4%) | 129 (24.1%) |
 101–200 | 76 (44.7%) | 244 (45.5%) |
 201–300 | 32 (18.8%) | 116 (21.6%) |
  > 300 | 7 (4.1%) | 47 (8.8%) |
 Missing or not tested | 131 | 384 |
Comorbidities (mild or worse)—No. (%) |  |  |
 Heart disease | 62 (21.6%) | 150 (18.1%) |
 Hypertension | 147 (51.2%) | 389 (47.0%) |
 Diabetes | 34 (11.8%) | 138 (16.7%) |
 Unknown | 14 | 93 |
Concurrent treatment, no. (%) | Â | Â |
 Antiretroviral | 180 (63.1%) | 576 (67.6%) |
 Hydroxy-chloroquine | 207 (72.6%) | 651 (76.4%) |
 Antibiotics | 118 (41.4%) | 443 (52.0%) |
 Steroids | 62 (21.8%) | 296 (34.7%) |
 LMW heparin | 66 (23.2%) | 175 (20.5%) |
 Unknown | 16 | 68 |
C-reactive protein—median (IQR) | 37.6 (14.7, 120.0) | 36.3 (13.7, 137.0) |
 Missing or not tested | 181 | 255 |